Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis

Clinical and Experimental Medicine

Volumn 12, Issue 4, 2012, Pages 241-245

  Panahi, Yunes ^a   Davoudi, Seyyed Masoud ^a   Madanchi, Nima ^a   Abolhasani, Ehsan ^b  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atopic dermatitis; Gamma interferon; Interleukin; Quality of life

Indexed keywords

GAMMA IMMUNEX; IMMUNOGLOBULIN E; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; EOSINOPHIL COUNT; FEMALE; HUMAN; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; QUALITY OF LIFE; SCORAD SCORE; SOMNOLENCE;

DERMATITIS, ATOPIC; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-4; INTERLEUKIN-6; IRAN; QUALITY OF LIFE; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84870416119     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-011-0164-3     Document Type: Article

References (32)

1. Wasserbauer N, Ballow M (2010) Atopic dermatitis. Am J Med 122(2):121-125
2. Dou YC, Hagstromer L, Emtestam L, Johansson O (2006) Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study. Arch Dermatol Res 298:31-37 (Pubitemid 43725210)
3. Herman SM, Vender RB (2003) Antihistamines in the treatment of dermatitis. J Cutan Med Surg 7(6):467-473
4. Broshtilova V, Gantcheva M (2010) Therapeutic hotline: cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis. Dermatol Ther 23(1):90-93
5. Haw S, Shin MK, Haw CR (2010) The efficacy and safety of long-term oral cyclosporine treatment for patients with atopic dermatitis. Ann Dermatol 22(1):9-15
6. Hughes R, Collins P, Rogers S (2008) Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol 33(6):710-711
7. Murray ML, Cohen JB (2007) Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 32(1):23-27 (Pubitemid 46006360)
8. Fleischer AB Jr, Boguniewicz M (2010) An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature. J Drugs Dermatol 9(5):488-498
9. Musiał J, Milewski M, Undas A, Kopin'ski P, Duplaga M, Szczeklik A (1994) Human recombinant interferon gamma in the treatment of atopic dermatitis. Pol Arch Med Wewn 92(6):499-506
10. Jang IG, Yang JK, Lee HJ, Yi JY, Kim HO, Kim CW, Kim TY (2000) Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 42(6):1033-1040
11. Hanifin JM, Schneider LC, Leung DYM et al (1993) Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 28:189-197 (Pubitemid 23053704)
12. Chang TT, Stevens SR (2002) Atopic dermatitis: the role of recombinant interferon-gamma therapy. Am J Clin Dermatol 3(3):175-183 (Pubitemid 34533777)
13. Jujo K, Renz H, Abe J, Gelfand EW, Leung DY (1992) Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. J Allergy Clin Immunol 90(3 Pt 1):323-331
14. Tenda Y, Yamashita M, Kimura MY, Hasegawa A, Shimizu C, Kitajima M, Onodera A, Suzuki A, Seki N, Nakayama T (2006) Hyperresponsive TH2 cells with enhanced nuclear factor-kappa B activation induce atopic dermatitis-like skin lesions in Nishikinezumi Cinnamon/Nagoya mice. J Allergy Clin Immunol 118(3):725-733 (Pubitemid 44301400)
15. Punnonen J, Punnonen K, Janse'n CT, Kalimo K (1993) Interferon (IFN)-alpha, IFN-gamma, interleukin (IL)-2, and arachidonic acid metabolites modulate IL-4-induced IgE synthesis similarly in healthy persons and in atopic dermatitis patients. Allergy 48(3):189-195 (Pubitemid 23125926)
16. Gruner S, Liebenthal C, Heusser C, Brinkmann V, Zwirner A, Reinicke C, Harnack K, Sönnichsen N, Volk HD (1991) The influence of interferon-gamma and interleukin-4 on IgE production in B lymphocytes of patients with atopic dermatitis. A possible criterion for selection of patients for interferon therapy. Acta Derm Venereol 71(6):484-487
17. Sato A, Tsuji K, Yamamura M, Morita Y, Kanzaki H, Tada J, Makino H, Arata J (1998) Increased type 2 cytokine expression by both CD4 + CD45RO + T cells and CD8 + CD45RO + T cells in blood circulation is associated with high serum IgE but not with atopic dermatitis. J Invest Dermatol 111(6):1079-1084 (Pubitemid 29115178)
18. Shibata S, Maeda S, Kondo N, Inoue A, Maeda S, Chimura N, Fukata T (2011) Effect of recombinant canine interferon-c on granulocyte-macrophage colony-stimulating factor, transforming growth factor-b and CC chemokine ligand 17 mRNA transcription in a canine keratinocyte cell line (CPEK). Vet Dermatol 22(1):24-30
19. Hattori K, Nishikawa M, Watcharanurak K, Ikoma A, Kabashima K, Toyota H, Takahashi Y, Takahashi R, Watanabe Y, Takakura Y (2010) Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J Immunol 184(5):2729-2735
20. Reinhold U, Kukel S, Brzoska J, Kreysel HW (1993) Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 29(1):58-63 (Pubitemid 23197197)
21. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ (1994) The U.K. working party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 131:383-396 (Pubitemid 24290226)
22. Williams HC, Burney PGJ, Pembroke AC, Hay RJ (1994) The UK working party's diagnostic criteria for atopic dermatitis III: Independent hospital validation. Br J Dermatol 131:406-416 (Pubitemid 24290228)
23. Williams HC, Burney PGJ, Strachan D, Hay RJ (1994) The UK working party's diagnostic criteria for atopic dermatitis II: observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 131:397-405 (Pubitemid 24290227)
24. Boguniewicz M, Jaffe HS, Izu A et al (1990) Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 88:365-370 (Pubitemid 20147271)
25. Costa C, Rilliet A, Nicolet M, Saurat JH (1989) Scoring atopic dermatitis. The simpler the better? Acta Derm Venereol(Stockh) 69:41-45 (Pubitemid 19028330)
26. Oranje AP, Glazenburg EJ, Wolkerstorfer A, De Waard-Van Der Spek FB (2007) Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 157:645-648 (Pubitemid 47389896)
27. Finlay A, Khan G (1994) Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210-216 (Pubitemid 24194579)
28. Schneider LC, Baz Z, Zarcone C, Zurakowski D (1998) Long term therapy with recombinant interferon-gamma for atopic dermatitis. Ann Allergy Asthma Immunol 80:263-268 (Pubitemid 28145315)
29. Steven SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD (1998) Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 134:799-804 (Pubitemid 28350182)
30. Musial J, Milewski M, Undas A, Kopinski P, Duplaga M, Szczeklik A (1995) Interferon-gamma in treatment of atopic dermatitis: influence on T-cell activation. Allergy 50:520-523
31. Takakura M, Takeshita F, Aihara M, Xin KQ, Ichino M, Okuda K, Ikezawa Z (2005) Hyperproduction of IFN-gamma by CpG oligodeoxynucleotide-induced exacerbation of atopic dermatitislike skin lesion in some NC/Nga mice. J Invest Dermatol 125(6):1156-1162
32. Simon MR, Cooper KD, Norris RB, Blok B, King CL (1995) Antigen presenting cell-independent cytokine and spontaneous in vitro IgE production in patients with atopic dermatitis: increased interferon-gamma production and lack of effects of in vivo lowdose interferon-gamma treatment. J Allergy Clin Immunol 96(1):84-91